アナキンラ
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study
Franzetti M, et al.〔J Immunol. 2021 Apr 1;206(7):1569-1575〕(査読済み)
Efficacy of early anti-inflammatory treatment with high doses IV Anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
Pontali E, et al.〔J Allergy Clin Immunol. 2021 Apr;147(4):1217-1225〕(査読済み)